m6A-centered Disease Response Information

General Information of the Disease (ID: M6ADIS0184)
Name
Triple-negative breast cancer
ICD
ICD-11: 2C6Z
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Disease
In total 11 item(s) under this disease
Crosstalk ID: M6ACROT03104
 Crosstalk Info 
m6A Regulator RNA demethylase ALKBH5 (ALKBH5)
 Regulator Info 
m6A Target long intergenic non-protein coding RNA 115 (LINC00115)
 Target Gene 
Epigenetic Regulator Histone-lysine N-methyltransferase SETDB1 (SETDB1)
Regulated Target Polo like kinase 3 (PLK3)
Crosstalk relationship Histone modification → m6A
Drug Acetaminophen
 Drug Info 
Crosstalk ID: M6ACROT03105
 Crosstalk Info 
m6A Regulator YTH domain-containing family protein 2 (YTHDF2)
 Regulator Info 
m6A Target long intergenic non-protein coding RNA 115 (LINC00115)
 Target Gene 
Epigenetic Regulator Histone-lysine N-methyltransferase SETDB1 (SETDB1)
Regulated Target Polo like kinase 3 (PLK3)
Crosstalk relationship Histone modification → m6A
Drug Acetaminophen
 Drug Info 
Crosstalk ID: M6ACROT03139
 Crosstalk Info 
m6A Regulator Methyltransferase-like 14 (METTL14)
 Regulator Info 
m6A Target Transcriptional coactivator YAP1 (YAP1)
 Target Gene 
Epigenetic Regulator Lysine-specific histone demethylase 1A (KDM1A)
Regulated Target Histone H3 lysine 4 dimethylation (H3K4me2)
Crosstalk relationship Histone modification → m6A
Crosstalk ID: M6ACROT03140
 Crosstalk Info 
m6A Regulator YTH domain-containing family protein 2 (YTHDF2)
 Regulator Info 
m6A Target Transcriptional coactivator YAP1 (YAP1)
 Target Gene 
Epigenetic Regulator Lysine-specific histone demethylase 1A (KDM1A)
Regulated Target Histone H3 lysine 4 dimethylation (H3K4me2)
Crosstalk relationship Histone modification → m6A
Crosstalk ID: M6ACROT03370
 Crosstalk Info 
m6A Regulator RNA demethylase ALKBH5 (ALKBH5)
 Regulator Info 
m6A Target Forkhead box protein O1 (FOXO1)
 Target Gene 
Epigenetic Regulator Histone-lysine N-methyltransferase SETDB1 (SETDB1)
Regulated Target Polo like kinase 3 (PLK3)
Crosstalk relationship Histone modification → m6A
Drug Doxil
 Drug Info 
Crosstalk ID: M6ACROT05023
 Crosstalk Info 
m6A Regulator ELAV-like protein 1 (ELAVL1)
 Regulator Info 
m6A Target Zinc finger E-box-binding homeobox 1 (ZEB1)
 Target Gene 
Epigenetic Regulator ZEB1 antisense RNA 1 (ZEB1-AS1)
Regulated Target ELAV-like protein 1 (HuR/ELAVL1)
Crosstalk relationship ncRNA → m6A
Crosstalk ID: M6ACROT05091
 Crosstalk Info 
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
 Regulator Info 
m6A Target Transcriptional coactivator YAP1 (YAP1)
 Target Gene 
Epigenetic Regulator piR-31115
Regulated Target Methyltransferase-like protein 3 (METTL3)
Crosstalk relationship ncRNA → m6A
Crosstalk ID: M6ACROT05092
 Crosstalk Info 
m6A Regulator Methyltransferase-like 3 (METTL3)
 Regulator Info 
m6A Target Transcriptional coactivator YAP1 (YAP1)
 Target Gene 
Epigenetic Regulator piR31115
Regulated Target Methyltransferase-like protein 3 (METTL3)
Crosstalk relationship ncRNA → m6A
Crosstalk ID: M6ACROT05167
 Crosstalk Info 
m6A Regulator Methyltransferase-like 3 (METTL3)
 Regulator Info 
m6A Target long intergenic non-protein coding RNA 662 (LINC00662)
 Target Gene 
Epigenetic Regulator hsa-miR-186-5p
Regulated Target Methyltransferase-like protein 3 (METTL3)
Crosstalk relationship ncRNA → m6A
Drug Docetaxel
 Drug Info 
Crosstalk ID: M6ACROT05168
 Crosstalk Info 
m6A Regulator Methyltransferase-like 3 (METTL3)
 Regulator Info 
m6A Target long intergenic non-protein coding RNA 662 (LINC00662)
 Target Gene 
Epigenetic Regulator Long intergenic non-protein coding RNA 662 (LINC00662)
Regulated Target hsa-miR-186-5p
Crosstalk relationship ncRNA → m6A
Drug Docetaxel
 Drug Info 
Crosstalk ID: M6ACROT05887
 Crosstalk Info 
m6A Regulator ELAV-like protein 1 (ELAVL1)
 Regulator Info 
m6A Target Zinc finger E-box-binding homeobox 1 (ZEB1)
 Target Gene 
Epigenetic Regulator ZEB1 antisense RNA 1 (ZEB1-AS1)
Regulated Target ELAV-like protein 1 (HuR/ELAVL1)
Crosstalk relationship m6A → ncRNA
References
Ref 1 In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689-95. doi: 10.1124/dmd.105.003681. Epub 2005 Mar 2.
Ref 2 Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J Med Chem. 1999 May 20;42(10):1803-15. doi: 10.1021/jm9806603.
Ref 3 Clinical pipeline report, company report or official report of Adagene.
Ref 4 AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6(7):e21487. doi: 10.1371/journal.pone.0021487. Epub 2011 Jul 18.
Ref 5 2011 Pipeline of Santaris Pharma.
Ref 6 Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
Ref 7 National Cancer Institute Drug Dictionary (drug id 741867).
Ref 8 Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998 Nov 10;98(19):2088-93. doi: 10.1161/01.cir.98.19.2088.
Ref 9 A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem. 2004 Sep 24;279(39):41124-30. doi: 10.1074/jbc.M401552200. Epub 2004 Jul 15.
Ref 10 Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. doi: 10.1021/jm980235+.